To investigate the specific role of Suv39h1-deficient T cells in the observed tumor rejection phenotype, we adoptively transferred in vitro activated control WT and Suv39h1-KO OVA-specific T cell receptor (TCR) transgenic OT-1 cells to B6 mice bearing established EL4-OVA tumors (Supplementary Fig. 1A). The gene discussed is SUV39H1; the disease is neoplasm.